Can a single dose of muscle cells hold up for years against stubborn incontinence?

NCT ID NCT06743620

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Cook MyoSite Source: ClinicalTrials.gov ↗

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This registry follows women who received iltamiocel — an experimental cell therapy — for stress urinary incontinence that came back or persisted after surgery. Researchers are tracking long-term safety and whether the benefit lasts. The goal is to see if this one-time treatment can offer a durable solution without the need for repeat procedures.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If the data show iltamiocel remains safe and effective over years, it could support a new treatment option for women with stubborn stress urinary incontinence.
What could go wrong
This is an observational registry, not a controlled trial, so it cannot prove cause and effect. Long-term risks or loss of benefit may still emerge.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STRESS URINARY INCONTINENCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

female stress incontinence Urinary Incontinence, Stress

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Virtual Site

    Harvard, Massachusetts, 01451, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.